Marcia K. Horn, JD

Chair, MET Crusaders
President and CEO, ICAN, International Cancer Advocacy Network

Marcia Horn is President and CEO of ICAN, the International Cancer Advocacy Network, and Chair of MET Crusaders. At the MET Crusaders, the top priority is supporting MET patients and care partners throughout their journeys. As a global, pan-tumor, multi-stakeholder biomarker group, the MET Crusaders aims to make MET-altered cancers manageable—and ultimately curable. Our MET Research Consortium, in development, will help advance that mission by accelerating innovative MET research.

Marcia is entering her 30th year as a patient navigator with ICAN. At ICAN, she has directly navigated many thousands of pan-tumor patient cases in the U.S. and in 93 countries since the founding of the organization in 1996. She is a molecular profiling advocate, a clinical trials matching advocate, an expanded access/compassionate use advocate, and a global access advocate. The pan-tumor Exon 20 Group (for EGFR exon 20 and HER2 exon 20 insertion mutated cancer patients), the NRG1 Energizers (for NRG1 fusion positive cancer patients), the PD-L1 Amplifieds (for CD 274 positive cancer patients), and the Biomarker Collaborative, are also under ICAN’s umbrella.

In 2012, Marcia became DIA’s inaugural chair of its Patient Engagement Community and in 2013 was named one of the first PCORI Ambassadors. In her role as a research advocate, Marcia served, from 2014 to 2022, as one of the two research advocates for the Stand Up 2 Cancer Molecular Early Detection of Colon Cancer Dream Team, and the Stand Up 2 Cancer InTIME Dream Team for Lung Cancer Interception. Since 2018, she has served as a research advocate for the National Cancer Institute’s University of Texas Southwestern/MD Anderson Cancer Center Lung SPORE (Specialized Program of Research Excellence) working with John Minna, MD, and John Heymach, MD, PhD.

Having served for eight years as member of the ASCO TAPUR Study Molecular Tumor Board, Marcia was invited to serve on the ASCO TAPUR Steering Group. She worked with Razelle Kurzrock, MD, chair of SWOG’s Early Therapeutics/Rare Cancers Committee, as the committee’s research advocate. Marcia is currently serving as the advocate for the IASLC’s Rare Tumors Committee and is the patient advocate for the NCI’s Investigational Drugs Steering Committee. She recently concluded 14 years as a member of the Banner Health Institutional Review Board.

In spring of 2026, she was invited by Roy Herbst, MD, PhD, and Katerina Politi, PhD, onto the External Advisory Board for the Yale SPORE in Lung Cancer. She accepted the invitation of City of Hope’s Ravi Salgia, MD, PhD, to join the Advisory Board for their ARPA-H award which includes the IMMUNO-BIOMAP clinical trial which tracks tumor evolution during immunotherapy and assigns patients to biomarker-matched sub-trials targeting their resistance mechanism.

Marcia is a Phi Beta Kappa graduate of Stanford University in Political Science and received her JD from the Stanford Law School. Before joining ICAN, she practiced litigation and appellate law in Phoenix and held major leadership positions in the Arizona arts and civic community. Her son Yoni practices corporate law in California.